NET ASSET VALUE – 28 February 2026
NET ASSET VALUE – 28 February 2026
2026-03-03 08:00:00
On the 28 February 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,281 million and NAV per share was SEK 42.36. Return on NAV per share in the month was -0.11%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 50% | 272 | 3.51 | 8.3% |
| Empros Pharma | 79% | 204 | 2.64 | 6.2% |
| Atrogi | 44% | 197 | 2.54 | 6.0% |
| KAHR Medical | 34% | 194 | 2.50 | 5.9% |
| Xspray Pharma | 18% | 192 | 2.48 | 5.9% |
| Bonsai Biotherapeutics | 100% | 156 | 2.01 | 4.7% |
| Lipum | 42% | 148 | 1.91 | 4.5% |
| Xintela | 60% | 141 | 1.82 | 4.3% |
| Microbiotica | 10% | 122 | 1.57 | 3.7% |
| AnaCardio | 13% | 79 | 1.02 | 2.4% |
| Mendus | 23% | 65 | 0.84 | 2.0% |
| Geneos Therapeutics | 15% | 65 | 0.83 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 53 | 0.68 | 1.6% |
| Vitara Biomedical | 11% | 51 | 0.66 | 1.6% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 1.0% |
| Egetis Therapeutics | 1% | 22 | 0.29 | 0.7% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2,013 | 25.99 | 61.4% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 6.2% |
| Symcel | 30% | 192 | 2.48 | 5.9% |
| Chromafora | 28% | 131 | 1.69 | 4.0% |
| Frontier Biosolutions | 2% | 26 | 0.33 | 0.8% |
| Nanologica | 44% | 15 | 0.19 | 0.5% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 565 | 7.30 | 17.2% | |
| Assets related to Portfolio companies | 236 | 3.04 | 7.2% | |
| Other assets and liabilities | 467 | 6.03 | 14.2% | |
| Net Asset Value | 3,281 | 42.36 | 100.0% | |